(Reuters) – Biogen Inc and partner Eisai Co Ltd said on Friday the U.S. Food and Drug Administration has extended the review period by three months for aducanumab, its experimental treatment for Alzheimer’s disease.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shounak Dasgupta)
